Oncode is the independent institute dedicated to outsmarting cancer and impacting lives.
Carl Figdor and Michiel Vermeulen participate in the Oncode Institute for Radboudumc and Radboud University, respectively.
Research programmeDespite enormous progress in our understanding of cancer, the chance of long-term survival remains small for many patients, particularly those with metastatic disease. Oncode will address this unmet clinical need through an innovative basic research programme. True innovation in the treatment of cancer relies on new insights into the basic mechanisms of oncogenesis, which in turn depend heavily on technological innovation. Oncode research will be guided by a number of key questions that need to be resolved to extend life expectancy and improve quality of life for cancer patients.
Principal scientific questionsThe key issues in cancer research today are summed up in our principal scientific questions:
- Can we define new and better targets for therapy on the basis of detailed analyses of tumours, tumour-derived cell lines and organoids, and xenografts?
- What is the basis for tumour heterogeneity, and how can we harness this knowledge to refine cancer therapy?
- What role does the cell of origin play in a tumour’s characteristics and responsiveness to therapy?
- How do cancer cells avoid host immune attack, and how can we stop them from doing so?
- How do non-mutated background genes influence tumour formation and response to therapy?
- Can we develop novel models to predict therapy response?
- How can we prevent metastatic disease?
Scientific themesOn the basis of these questions, Oncode’s founding scientists have identified six scientific themes that constitute the basis of the integrated research strategy:
- Development of novel technologies
- Understanding the critical drivers of tumour growth and the causes of resistance
- Analysis of network perturbations in tumours and tumour-host interactions
- Causes and consequences of genetic instability
- Identification of critical drug combinations and biomarkers for personalized cancer treatments
- Mobilizing immune defence
Read more on the Oncode website.
Related news items
Valentine’s day spectacle at the Radboud Research Rounds21 February 2019
This year’s Valentine’s day in the Radboudumc was focused on the RRR of the Tumors of the Digestive Tract. In the biannual Paper Award session the big prize went to Daniel Garza from the Center for Molecular and Biomolecular Informatics, for his paper on “the environmental metabolome”.read more
New infection route resistant hospital bacteria discovered21 February 2019
In a case study on JAMA Network Open, physician microbiologist Joost Hopman describes how the rare bacterium Pseudomonas aeruginosa could spread infection from shower drains in patient rooms.read more
Optimal dosing of anti-HIV drug darunavir in pregnant women21 February 2019
In the Journal of Antimicrobial Chemotherapy Stein Schalkwijk, Rob ter Heine, Angela Colbers and David Burger investigated how pregnant women should be treated with the anti-HIV drug darunavir.read more
Celebrations to mark the retirement of Joost Schalkwijk21 February 2019
With a mini symposium (‘Oppervlakkig en toch diepgaand’) and reception a passionate researcher of the RIMLS said farewell. After 36 working years Joost Schalkwijk, theme Inflammatory diseases, will enjoy his retirement.read more
Ultrahigh-resolution MRI reveals structural brain differences in serotonin transporter knockout rats after sucrose and cocaine self-administration20 February 2019
In Addiction Biology Peter Karel and Judith Homberg showed that rats lacking the serotonin transporter show increased cocaine, but unaltered sucrose, self-administration.read more